American Society of Clinical Oncology

SHERPA: White

People

  1. Hudis
    Hudis
  2. Scher
    Scher
  3. Motzer
    Motzer
  4. Saltz
    Saltz
  5. Kris
    Kris
  6. Bajorin
    Bajorin
  7. Norton
    Norton
  8. Patil
    Patil
  9. Wolchok
    Wolchok
  10. Morris
    Morris

Groups

  1. Solid Tumor Oncology Division (2144)
  2. Surgery (848)
  3. Genitourinary Disease Management Team (783)
  4. Survivorship Research (754)
  5. Genitourinary Oncology Service (700)
  6. Epidemiology and Biostatistics (624)
  7. Population Sciences Research Program (621)
  8. Breast Cancer Disease Management Team (618)
  9. Gastrointestinal Disease Management Team (601)
  10. Thoracic Malignancies Disease Management Team (572)
Search Within
Refine Results
Formats
  1. Meeting Abstract (2080)
  2. Journal Article (1844)
  3. Conference Paper (1)
Groups
  1. Solid Tumor Oncology Division (2144)
  2. Surgery (848)
  3. Genitourinary Disease Management Team (783)
  4. Survivorship Research (754)
  5. Genitourinary Oncology Service (700)
  6. Epidemiology and Biostatistics (624)

More Groups

People
  1. Robert Motzer (207)
  2. Howard Scher (204)
  3. Clifford Hudis (198)
  4. Leonard Saltz (174)
  5. Dean Bajorin (148)
  6. Mark Kris (143)

More People

Years
  1. 2019 (9)
  2. 2018 (231)
  3. 2017 (114)
  4. 2016 (216)
  5. 2015 (508)
  6. 2014 (446)

More Years

Publications
  1. Journal of Clinical Oncology (3732)
  2. Journal of Oncology Practice (103)
  3. American Society of Clinical Oncology Educational Book (88)
  4. ASCO Connection (1)
  5. ASCO News & Forum (1)

Results (3925)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT)
    Meeting Abstract

    McHugh, D. J.; Funt, S.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naive prostate cancer that retains RB expression
    Meeting Abstract

    Kelly, W. K.; Godwin, J. L.; Hoffman-Censits, J. H.; Knudsen, K. E.; De Leeuw, R.; Leiby, B. E.; Southwell, T.; Hubert, C.; Smith, D. C.; Chatta, G. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer
    Meeting Abstract

    Mahal, B. A. V.; Yang, D. D.; Wang, N.; Alshalalfa, M.; Davicioni, E.; Choeurng, V.; Spratt, D. E.; Martin, N. E.; Mouw, K. W.; Orio, P. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs
    Meeting Abstract

    Morris, M. J.; Vogelzang, N. J.; Sartor, A. O.; Armour, A. A.; Messmann, R. A.; Groaning, M.; Robarts, A.; Tolcher, A. W.; Gordon, M. S.; Babiker, H. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma
    Meeting Abstract

    Motzer, R. J.; Grunwald, V.; Hutson, T. E.; Porta, C.; Powles, T.; Eto, M.; Dutcus, C. E.; Baig, M. A.; Dutta, L.; Li, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer
    Meeting Abstract

    Hoimes, C. J.; Petrylak, D. P.; Flaig, T. W.; Carret, A. S.; Melhem-Bertrandt, A.; Rosenberg, J. E.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis
    Meeting Abstract

    Hwang, W. L.; Tendulkar, R. D.; Niemierko, A.; Agrawal, S.; Stephans, K. L.; Spratt, D. E.; Hearn, J. W. D.; Koontz, B. F.; Lee, W. R.; Michalski, J. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Integrative molecular profiling challenges robustness of prognostic signature scores in multifocal prostate cancer
    Meeting Abstract

    Hovelson, D.; Salami, S. S.; Kaplan, J. B.; Mathieu, R.; Udager, A.; Curci, N.; Lee, M.; De La Vega, L. L.; Susani, M.; Rioux-Leclercq, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Next generation sequencing of urothelial bladder cancer: Memorial Sloan Kettering Cancer Center experience in 454 patients
    Meeting Abstract

    Isharwal, S.; Audenet, F.; Drill, E. N.; Ostrovnaya, I.; Pietzak, E. J.; Al-Ahmadie, H.; Cha, E. K.; Donahue, T. F.; Teo, M. Y.; Funt, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Association of somatic mutational burden with depression and anxiety in patients with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Bergerot, C. D.; Clark, K. L.; Bergerot, P. G.; Ashing, K. T.; Hahn, A. W.; Obenchain, R.; Dizman, N.; Hsu, J.; Philip, E. J.; Loscalzo, M. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save